Opinion

Video

Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Video content above is prompted by the following:

  1. What additional factors do you consider when determining the most effective sequence of these therapies (FTD/TPI plus bevacizumab, fruquintinib, regorafenib)?
  2. What future research is needed to better understand the optimal sequencing of these therapies?
Related Videos
Marc Humbert, MD, PhD
John Ostrominski, MD
John Buse, MD, PhD
Christian T. Ruff, MD, MPH
Dr Geoffrey Rutledge
Jason Bellet of Eko Health
Dr Geoffrey Rutledge
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo